David Squillacote

2.3k total citations
18 papers, 1.2k citations indexed

About

David Squillacote is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, David Squillacote has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 11 papers in Pediatrics, Perinatology and Child Health and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in David Squillacote's work include Epilepsy research and treatment (13 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Neuroscience and Neuropharmacology Research (6 papers). David Squillacote is often cited by papers focused on Epilepsy research and treatment (13 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Neuroscience and Neuropharmacology Research (6 papers). David Squillacote collaborates with scholars based in United States, Italy and United Kingdom. David Squillacote's co-authors include Gregory L. Krauss, Antonio Laurenza, Haichen Yang, Bernhard J. Steinhoff, Dinesh Kumar, Jacqueline A. French, Jin Zhu, Elinor Ben‐Menachem, Michelle Gee and Lynn D. Kramer and has published in prestigious journals such as Neurology, Epilepsia and Movement Disorders.

In The Last Decade

David Squillacote

17 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Squillacote United States 12 937 783 766 141 100 18 1.2k
Philipp S. Reif Germany 21 752 0.8× 557 0.7× 382 0.5× 95 0.7× 73 0.7× 44 997
Marina Nikanorova Denmark 16 734 0.8× 535 0.7× 364 0.5× 51 0.4× 93 0.9× 29 943
Kenou van Rijckevorsel Belgium 18 737 0.8× 450 0.6× 352 0.5× 150 1.1× 83 0.8× 45 1.1k
Masakazu Seino Japan 17 651 0.7× 384 0.5× 362 0.5× 78 0.6× 117 1.2× 98 839
F. J. Ritter United States 6 715 0.8× 493 0.6× 247 0.3× 39 0.3× 53 0.5× 11 804
Kate Riney Australia 13 975 1.0× 567 0.7× 363 0.5× 70 0.5× 236 2.4× 32 1.4k
J. P. Mumford United Kingdom 18 1.1k 1.2× 818 1.0× 456 0.6× 84 0.6× 151 1.5× 26 1.4k
A. Scaramelli Uruguay 10 416 0.4× 236 0.3× 189 0.2× 95 0.7× 115 1.1× 21 613
Paul B. Augustijn Netherlands 13 278 0.3× 344 0.4× 347 0.5× 247 1.8× 76 0.8× 17 740
Ursula Falter Belgium 7 700 0.7× 646 0.8× 367 0.5× 20 0.1× 45 0.5× 7 810

Countries citing papers authored by David Squillacote

Since Specialization
Citations

This map shows the geographic impact of David Squillacote's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Squillacote with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Squillacote more than expected).

Fields of papers citing papers by David Squillacote

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Squillacote. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Squillacote. The network helps show where David Squillacote may publish in the future.

Co-authorship network of co-authors of David Squillacote

This figure shows the co-authorship network connecting the top 25 collaborators of David Squillacote. A scholar is included among the top collaborators of David Squillacote based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Squillacote. David Squillacote is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Vázquez, Blanca, David Squillacote, Eric Q. Wu, et al.. (2015). Healthcare resource utilization associated with rescue Medication use in adult Patients With Seizure Clusters: a retrospective chart Review. Value in Health. 18(3). A289–A290. 5 indexed citations
3.
Kramer, Lynn D., Andrew Satlin, Gregory L. Krauss, et al.. (2014). Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies. Epilepsia. 55(3). 423–431. 50 indexed citations
4.
Sperling, Michael R., Kevin F. Haas, Gregory L. Krauss, et al.. (2014). Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy. Epilepsia. 55(10). 1544–1550. 23 indexed citations
5.
Krauss, Gregory L., Emilio Perucca, Elinor Ben‐Menachem, et al.. (2014). Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia. 55(7). 1058–1068. 88 indexed citations
6.
Steinhoff, Bernhard J., Elinor Ben‐Menachem, Philippe Ryvlin, et al.. (2013). Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 54(8). 1481–1489. 202 indexed citations
7.
Rascol, Olivier, Paolo Barone, Madhuri Behari, et al.. (2012). Perampanel in Parkinson Disease Fluctuations. Clinical Neuropharmacology. 35(1). 15–20. 45 indexed citations
8.
French, Jacqueline A., Gregory L. Krauss, Bernhard J. Steinhoff, et al.. (2012). Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305. Epilepsia. 54(1). 117–125. 338 indexed citations
9.
Rektor, Ivan, Gregory L. Krauss, Michal Bar, et al.. (2012). Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurologica Scandinavica. 126(4). n/a–n/a. 66 indexed citations
10.
11.
Kramer, L. D., Emilio Perucca, Elinor Ben‐Menachem, et al.. (2012). Perampanel, a Selective, Non-Competitive AMPA Receptor Antagonist as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures: A Dose Response Analysis from Phase III Studies (P06.117). Neurology. 78(Meeting Abstracts 1). P06.117–P06.117. 8 indexed citations
12.
Hussein, Zanariah, et al.. (2012). Demographic Factors and Concomitant Antiepileptic Drugs Have No Effect on the Pharmacodynamics of Perampanel (P06.127). Neurology. 78(Meeting Abstracts 1). P06.127–P06.127. 13 indexed citations
13.
Krauss, Gregory L., Emilio Perucca, Matthew A. Brodie, et al.. (2012). Pooled Analysis of Responder Rates and Seizure Freedom from Phase III Clinical Trials of Adjunctive Perampanel, a Selective, Non-Competitive AMPA Receptor Antagonist (PD3.010). Neurology. 78(Meeting Abstracts 1). PD3.010–PD3.010. 1 indexed citations
14.
Krauss, Gregory L., Michal Bar, Victor Biton, et al.. (2011). Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurologica Scandinavica. 125(1). 8–15. 82 indexed citations
15.
Lees, Andrew J., Stanley Fahn, Karla Eggert, et al.. (2011). Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease. Movement Disorders. 27(2). 284–288. 59 indexed citations
16.
Eggert, Karla, David Squillacote, Paolo Barone, et al.. (2010). Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study. Movement Disorders. 25(7). 896–905. 58 indexed citations
17.
Squillacote, David, Miguel Ángel González Martínez, & William Sheremata. (1996). Natural Alpha Interferon in Multiple Sclerosis: Results of Three Preliminary Series. Journal of International Medical Research. 24(3). 246–257. 8 indexed citations
18.
Squillacote, David, et al.. (1980). The emergency services physician assistant: Results of two years' experience. Annals of Emergency Medicine. 9(2). 96–99. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philipp S. Reif Breakdown of academic impact, for papers by Marina Nikanorova Breakdown of academic impact, for papers by Kenou van Rijckevorsel Breakdown of academic impact, for papers by Masakazu Seino Breakdown of academic impact, for papers by F. J. Ritter Breakdown of academic impact, for papers by Kate Riney Breakdown of academic impact, for papers by J. P. Mumford Breakdown of academic impact, for papers by A. Scaramelli Breakdown of academic impact, for papers by Paul B. Augustijn Breakdown of academic impact, for papers by Ursula Falter
Rankless by CCL
2026